Indivior PLC, encompassing its various subsidiaries, is a pharmaceutical firm dedicated to the research, production, and global commercialization of prescription medications. These therapies primarily utilize buprenorphine to treat opioid dependence and associated medical conditions. The company's development pipeline is actively exploring novel treatments for opioid use disorder (OUD) and schizophrenia.